<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972201</url>
  </required_header>
  <id_info>
    <org_study_id>RSCD2020006</org_study_id>
    <nct_id>NCT04972201</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy</brief_title>
  <acronym>PROMISE</acronym>
  <official_title>The Performance of a Pan-cancer Early Detection Model Based on Liquid Biopsy of Various-omics Biomarkers: a Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Burning Rock Dx Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROMISE is a multi-center, prospective and proof of concept study aimed to evaluate the&#xD;
      performance of 3 prototype assays of cell-free DNA (cfDNA) mutation, cfDNA methylation and&#xD;
      microRNA (miRNA) expression in early detection of multi-cancer. Assay(s) will be selected for&#xD;
      further development. The study will enroll approximately 2035 participants, including&#xD;
      participants with cancers and healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of early detection of cancers and Tissue of origin (TOO) accuracy of 3 assays of cfDNA mutation, cfDNA methylation and miRNA expression when specificity was 90%, 95% or 98% in healthy participants</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity and TOO accuracy of an assay of cfDNA mutation in various types of cancer in different stages</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity and TOO accuracy of an assay of cfDNA methylation in various types of cancer in different stages</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity and TOO accuracy of an assay of miRNA expression in various types of cancer in different stages</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity and TOO accuracy of combined assays of cfDNA mutation, cfDNA methylation and/or miRNA expression in early detection of cancers</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2305</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer Arm</arm_group_label>
    <description>Participants with new diagnosis of cancer, from whom blood samples will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Arm</arm_group_label>
    <description>Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi-cancer early detection test</intervention_name>
    <description>Blood collection and multi-cancer early detection test</description>
    <arm_group_label>Cancer Arm</arm_group_label>
    <arm_group_label>Healthy Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants will be re recruited from medical centers and assigned into two arms,&#xD;
        including participants with new diagnosis of cancers and healthy participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Ability to provide a written informed consent&#xD;
&#xD;
          -  40-75 years old&#xD;
&#xD;
          -  Ability to comply with study procedures&#xD;
&#xD;
          -  Confirmed diagnosis or suspicious cases of one of the 9 types of cancers within 42&#xD;
             days prior to study blood draw.&#xD;
&#xD;
          -  No prior anti-cancer therapy (local or systematic) prior to study blood draw&#xD;
&#xD;
        Exclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow&#xD;
             transplant or stem cell transplant&#xD;
&#xD;
          -  Recipients of blood transfusion within 7 days prior to study blood draw&#xD;
&#xD;
          -  Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to&#xD;
             diseases other than cancer&#xD;
&#xD;
          -  Known prior diagnosis of malignancies, other current malignant diseases or multiple&#xD;
             primary tumors&#xD;
&#xD;
          -  No confirmed diagnosis of cancer by histopathological or radiological assessments&#xD;
             within 42 days of study blood draw, or diagnosis of a benign disease or precancerous&#xD;
             lesions by histopathological assessments, or inability to characterize whether the&#xD;
             lesion is malignant or benign&#xD;
&#xD;
        Inclusion Criteria for Healthy Arm Participants:&#xD;
&#xD;
          -  Ability to provide a written informed consent&#xD;
&#xD;
          -  40-75 years old&#xD;
&#xD;
          -  No cancer-related symptoms or discomfort within 30 days prior to study blood draw&#xD;
&#xD;
          -  Ability to comply with study procedures&#xD;
&#xD;
          -  No clinically significant finding by laboratory tests and radiology examinations&#xD;
&#xD;
        Exclusion Criteria for Healthy Arm Participants:&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow&#xD;
             transplant or stem cell transplant&#xD;
&#xD;
          -  Recipients of blood transfusion within 7 days prior to study blood draw&#xD;
&#xD;
          -  Clinically significant or uncontrolled comorbidities&#xD;
&#xD;
          -  Prior or ongoing treatment of cancer within 3 years prior to study blood draw&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiachen Xu, M.D.</last_name>
    <phone>+86-10-87788029</phone>
    <email>XJCwelcome@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shangli Cai, Ph.D.</last_name>
    <phone>+86-21-61631938</phone>
    <email>shangli.cai@brbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiachen Xu, M.D.</last_name>
      <phone>+86-10-87788029</phone>
      <email>XJCwelcome@126.com</email>
    </contact>
    <investigator>
      <last_name>Jie Wang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>cell-free DNA (cfDNA)</keyword>
  <keyword>microRNA (miRNA)</keyword>
  <keyword>early detection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

